LWBK1006-Index LWW-Govindan-Review December 19, 2011 19:14
616 Index
Pancreatic intraepithelial neoplasms
(PanIN), 243, 247–248
Pancytopenia, 447
p53 and DNA damage, 98, 102
Panhypopituitarism, 223
PanIN.SeePancreatic
intraepithelial neoplasms
(PanIN)
Panitumumab, 273, 277
Papillary mesothelioma, surgical
resection in, 490, 494
Papillary serous adenocarcinoma,
477
Papillary thyroid carcinoma, 356,
363
dedifferentiated, 351, 359
poor prognostic features of, 351,
359
RET/PTC rearrangement in, 351,
359
and thyroid hormone
replacement, 349, 358
total thyroidectomy for, 349, 358
Papillomatous lesions, 160
Parameningeal disease, 409
Paraneoplastic neurologic
syndromes, 53
Paraneoplastic pemphigus, 224
Paraneoplastic syndromes, 217,
222, 223–224, 517–524
Parathyroid carcinoma, 353, 361
genetic defects with, 353, 361
management of, 353, 360
Parents with cancer, guidelines for,
561, 567
Parosteal osteosarcoma, 373
treatment, 368, 373
PARP.SeePoly (ADP-ribose)
polymerase (PARP)
PARP1, 331, 341
Partial response (PR), 96, 101, 452,
456
Parvovirus B19 infection, 544, 549
Patient-reported outcomes, in
oncology research, 116, 120
PCI.SeeProphylactic cranial
irradiation (PCI)
PCNSL.SeePrimary CNS
lymphoma (PCNSL)
PCR.SeePolymerase chain reaction
(PCR)
PC-SPES, for prostate cancer
treatment, 591, 595
11p, deletion of, 478
Pelvic floor exercises, 576, 579
Pelvic lymphadenectomy, 327
Pelvic percutaneous biopsies and
ovarian cancer, 162
Pemetrexed, 24, 32, 124, 129
for NSCLC treatment, 206, 211
Penetrance, defined, 150, 155
Penile cancer, 295
and HPV, 39, 51
P450 enzymes 1A1, 1A2 and
cigarette smoke, 33, 43
Peptic ulcers treatment, radiation
in, 59, 64
Peptidome, 3, 10
Percutaneous biliary drainage, 163,
172
Percutaneous cholecystostomy, 163,
172–173
Percutaneous gastrostomy tubes,
162, 171
Percutaneous nephrostomy, 163,
171
Performance status (PS), 206
Pericardial cysts, occurrence of, 222
Pericytes, 21, 29
Peripheral blood mobilized stem
cell allografts, 528, 534
Peripheral nerve blocks, for cancer
pain, 565, 570
Peripheral primitive
neuroectodermal tumor
(pPNET), 395, 405
Peripheral T cell lymphomas
(PTCL), 435
Peritoneal carcinomatosis, 477,
487–495
appendiceal cancer and, 487
BRCA1 mutation and, 480
extra-abdominal organs and, 487
free-floating tumor cells, 487, 492
intra-abdominal viscera and, 487
isolated, 487, 492
magnetic resonance imaging for,
488, 492
ovarian cancer and, 487
peritoneal lining and, 487
pressure-burst phenomenon, 487,
492
surgical intervention in, 489, 493
tumors in, 487, 492
Peritoneal mesothelioma, 484, 485
epithelial type of, 489, 494
malignant, 490, 494
risk factor for, 489, 494
surgical cytoreduction and
intraperitoneal
chemotherapy, 490, 494
Peritoneal shunts, 495
Peritoneovenous shunt, 512, 515
PET.SeePositron emission
tomography (PET)
Peutz-Jeghers syndrome, 154, 160,
332, 341
Phantom-hCG, 322, 329–330
Phenothiazines, 552
Phenotypic markers, analysis of,
72, 76
Phenytoin, 526, 532
Pheochromocytoma, 356, 362–363
Philadelphia chromosome, 448
in ALL, 452, 457
in AML, 452, 457
in CML, 452, 457
Phosphatidylinositol 3 kinase
signaling, 15
Phosphoinositide 3 (PI3), 25
Phospholipase C proteins, 7, 16
Phospholipid lipid growth factor
(PLGF), 20
Photons, skin-sparing effect of, 93
Physically inactive
colon cancer risk and, 62, 68
postmenopausal breast cancer
and, 62, 68
Physical therapy, 577
Physician-assisted suicide, 586
PI3.SeePhosphoinositide 3 (PI3)
PI3-kinase/AKT pathway, mTOR
in, 19
PI3-kinase pathway and mTOR, 32
Pilocarpine, 577
xerostomia and, 554, 558
Pilocytic astrocytoma, 384, 389
PIN.SeeProstate intraepithelial
neoplasia (PIN)
p16INK4a, 2, 8
expression of, 6, 14
Placental alkaline phosphatase
(PLAP), 297, 301
Plasma cell leukemia
diagnostic criterion for, 473
incidence of, 467
Plasma cell neoplasms, 463–473
Plasmacytoma, solitary bone,
472–473
Platelet-derived growth factor
receptor, 6
Platinum analogs, 573, 577
Platinum-based chemotherapy
Merkel cell carcinoma and, 378,
381
for ovarian cancer, 308, 309, 312,
314
Pleural mesothelioma and asbestos,
57, 63
PLGF.SeePhospholipid lipid
growth factor (PLGF)
Plicamycin, for reduction in
calcium level, 508
Plummer-Vinson syndrome, 142,
145
PLX4032 drug andBRAFgene, 24,
32